Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender.
• People who have been diagnosed with CD20-positive marginal zone lymphoma (a type of slow-growing blood cancer), confirmed by a tissue sample, including the subtypes known as MALT, SMZL, or NMZL, with at least one measurable area of disease.
• People with gastric (stomach) MALT lymphoma at a certain stage who meet specific treatment indicators, such as having symptoms related to the lymphoma, gastrointestinal bleeding (where the bleeding is under control or assessed as suitable by the trial doctor), organ damage, a large tumour mass, or disease that is continuing to grow.
• People with newly diagnosed non-stomach MALT or NMZL at an advanced stage who meet certain disease activity indicators, such as having multiple enlarged lymph node areas, a large lymph node or lesion, B symptoms (such as night sweats, fever, or weight loss), an enlarged spleen, fluid build-up, low blood counts caused by the disease, or rapidly progressing disease.
• People with newly diagnosed SMZL who have a progressively enlarging or painful spleen, or low blood counts caused by the disease.
• People who have not had prior systemic (whole-body) treatment for this lymphoma; people whose lymphoma has progressed, come back, or is not suitable for further local treatment after previous local treatments (such as surgery, radiation, antibiotic therapy for a stomach bacteria called H. pylori lasting at least 12 months, or hepatitis C treatment) may also be considered.
• People who are generally well enough to carry out normal daily activities, as measured by a standard medical scoring scale (ECOG score of 0–2).
• People whose blood counts, liver function, kidney function, and pancreas enzyme levels fall within the ranges required by the trial (confirm specific values with the trial site).
• People whose blood clotting function falls within an acceptable range, as measured by a standard test (INR at or below 1.5 times the upper normal limit).
• People whose life expectancy is at least 12 months.
• People who are willing to sign a written consent form before the trial screening begins.

Who may not be able to join:

• People who currently have, or have previously been diagnosed with, another cancer — unless they completed curative treatment and have had no signs of recurrence or spread for the past 5 years (some fully cured skin or cervical cancers may be exceptions — confirm with trial site).
• People whose lymphoma has spread to the brain or spinal cord, or whose lymphoma has transformed into a more aggressive type.
• People with serious or uncontrolled heart conditions, including severe heart failure, unstable chest pain, a heart attack within the past 6 months, certain abnormal heart rhythms, a weak pumping function of the heart, certain inherited heart muscle diseases, a history of abnormal heart electrical signals (QT interval), coronary heart disease requiring treatment, or high blood pressure that cannot be controlled even with multiple medications.
• People who have had active bleeding within the 2 months before screening, are currently taking blood-thinning medications, or are considered by the trial doctor to have a clear risk of bleeding.
• People who have had a blood clot in a deep vein or in the lungs within the past 6 months.
• People who have had major surgery (performed under general anaesthesia) within 6 weeks before screening, or a minor procedure within 2 weeks before screening (diagnostic endoscopies and placement of vascular access devices are generally not considered exclusions — confirm with trial site).
• People with an active infection, or uncontrolled hepatitis B or C, HIV/AIDS, or other serious infectious diseases.
• People with severe lung function impairment due to conditions such as lung scarring, interstitial lung disease, dust-related lung disease, radiation damage to the lungs, or drug-related lung inflammation.
• People who are pregnant, breastfeeding, or of childbearing potential and unwilling to use contraception during the trial.
• People who need to continuously take certain medications that strongly affect the way the body processes a specific liver enzyme pathway (CYP3A) — confirm specific medications with the trial site.
• People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.